These findings suggest that GSTM5 may also represent a potential therapeutic target in certain cancer contexts, particularly through redox-modulating or epigenetic-based strategies such as demethylating agents, although its role in PC remains largely unexplored. Here, GSTM5 is linked to pachyonychia congenita.